Royalty Pharma Q3 2023: $637M Adj Cash Receipts (+7% YoY); raises FY23 guidance

Royalty Pharma plc

2023-Q3 EPS reported $1.43 revenue$1,758,486,000

Adjusted Cash Receipts of $637M (+7% YoY); operating cash flow $574M (+6%).
Raised FY 2023 guidance for Adjusted Cash Receipts to $2,950M-$3,000M (prev. $2,900M-$2,975M).
Year-to-date announced transactions of up to $3.8B, including $2.1B in upfront payments.
CF franchise royalties $238M (+14%); Trelegy $58M (+36%); Evrysdi $16M (+64%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Royalty Pharma plc updated its the quarter ended September 30, 2023 guidance (raised).

Period: the quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 8, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.